Shunnichi Kashida

Company: xFOREST Therapeutics Co. Ltd.

Job title: Co-Founder, Representative Director, President & Chief Executive Officer

Seminars:

Comprehensive Interactome Profiling for Screening & Optimizing RNA Binders with High Affinity & Selectivity 3:30 pm

Highly structured RNA exhibit potential for high affinity with small molecules vitro interactome profiling of 30,000~ drug-like compounds vs. 2,000~ RNA structures extracted from disease related RNA SAR analyses of target binding modes at single-nucleotide resolution and binding selectivity among compound derivativesRead more

day: Conference Day One

Fireside Chat – Discussing How to Develop Assays for Accurate Validation of RNA Binding to Fast-Track Candidates Towards Patients 11:00 am

How is the field currently approaching validating RNA targets and what learnings can be taken from validating protein targets? Given there is no one size fits all model, how can you approach translating validation assays between different targets to reduce the time between finding a hit and then developing into a lead? How much customization…Read more

day: Conference Day One